Furthermore, previous studies suggest a strong rationale for combination antioxidant and iron chelator therapy as a two-pronged approach to counter the oxidative stress exhibited in PD [42,87], but also because iron has been associated with many of the other hallmarks of PD such as alpha synuclein aggregation [88,89,90], neuroinflammation [91,92] and mitochondrial dysfunction [11,16]. This evidence concerns the gene SNCA and Parkinson disease.